WP
RGNX icon

Woodline Partners’s Regenxbio RGNX Stock Holding History

Woodline Partners’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100,000
Closed -$1.17M – 691
2024
Q2 		$1.17M Sell
100,000
-46,334
-32% -$721K 0.01% 450
2024
Q1 		$3.08M Buy
+146,334
New +$2.6M 0.03% 404
2023
Q2 		– Sell
-305,822
Closed -$5.78M – 732
2023
Q1 		$5.78M Sell
305,822
-214,813
-41% -$4.75M 0.08% 271
2022
Q4 		$11.8M Buy
+520,635
New +$11.8M 0.16% 180
2021
Q1 		– Sell
-48,329
Closed -$2.19M – 469
2020
Q4 		$2.19M Sell
48,329
-227,113
-82% -$7.94M 0.06% 193
2020
Q3 		$7.58M Buy
275,442
+133,731
+94% +$4.36M 0.25% 102
2020
Q2 		$5.22M Sell
141,711
-12,910
-8% -$481K 0.21% 110
2020
Q1 		$5.01M Buy
+154,621
New +$6.44M 0.36% 87

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Woodline Partners's RGNX Position: Q3 2024 in Review

Woodline Partners sold out of Regenxbio (RGNX) in Q3 2024, closing a stake of 100,000 shares — an estimated $1.17M sold.

Woodline Partners first reported a position in RGNX in Q1 2020 and held it in 8 quarters. The position peaked at $11.8M in Q4 2022. 186 funds tracked by Wall St. Rank hold RGNX as of Q3 2024.

  • Woodline Partners reported no remaining Regenxbio position as of Q3 2024 after selling out during the quarter.
  • Woodline Partners sold 100,000 Regenxbio shares in Q3 2024, an estimated $1.17M.
  • Woodline Partners first reported a position in Regenxbio in Q1 2020 and held it in 8 quarters.
  • Woodline Partners's Regenxbio position peaked at $11.8M in Q4 2022.
  • 186 funds tracked by Wall St. Rank held Regenxbio as of Q3 2024.

Based on Woodline Partners's 13F filing for Q3 2024, filed 14 Nov 2024.